Table 1.
ANOVA-derived maximum observed ALA enantiomer geometric LS mean plasma concentrations (Cmax) and the corresponding 95% CI by treatment
| R-(+) Cmax LS means and CI
|
S-(−) Cmax LS means and CI
|
R/S Cmax ratio | |||||
|---|---|---|---|---|---|---|---|
| Treatment | Geometric mean (ng · mL−1) | 95% CI
|
Geometric mean (ng · mL−1) | 95% CI
|
|||
| Lower | Upper | Lower | Upper | ||||
| OS 600 | 7,843.8 | 6,670.2 | 9,223.9 | 3,785.9 | 3,232.3 | 4,434.2 | 2.07 |
| T 200 | 3,375.1 | 2,551.7 | 4,464.2 | 1,715.9 | 1,307.1 | 2,252.6 | 1.97 |
| T 300 | 3,591.9 | 2,731.3 | 4,723.7 | 1,846.5 | 1,391.2 | 2,451.0 | 1.95 |
| T 600 | 2,822.5 | 2,171.8 | 3,668.2 | 1,405.9 | 1,072.3 | 1,843.4 | 2.01 |
Note: Complete study population; N=24 (12 males/12 females).
Abbreviations: ANOVA, analysis of variance; ALA, alpha-lipoic acid; LS, least squares; Cmax, maximum observed plasma concentration; CI, confidence interval; OS, orally administered ALA solution; T 200, 200 mg tablet; T 300, 300 mg tablet; T 600, 600 mg tablet; N, number.